Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Pemetrexed 6pembrolizumab 5Magnetic Resonance Spectroscopy 5Carboplatin 5Specimen Handling 4Mastectomy, Segmental 4Cisplatin 4Bevacizumab 4durvalumab 2Platinum 2Biopsy 2tislelizumab 1osimertinib 1methyl-4-fluoro-4-deoxyglucose 1methoxyamine 1fludarabine phosphate 1devimistat 1dehydroftorafur 1defactinib 1dapagliflozin 1capmatinib 1aflutinib 1Standard of Care 1Smoking Devices 1Radiotherapy 1Radiation 1RO5126766 1Practice Guidelines as Topic 1Observation 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Adenocarcinoma of Lung × methoxyamine × Clear all
NCT05198830 2026-05-27

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
42 enrolled
Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡